“This is basically a game of corporate three-card monte.”
Likening Biogen to a sidewalk confidence game is how one particularly cynical portfolio manager of a biotech hedge fund responded when I asked for his take on Tuesday’s shocking biotech news: Biogen’s decision to resurrect its experimental Alzheimer’s drug aducanumab — and pursue regulatory approval — based on a new and more positive analysis from two large clinical trials previously thought to be negative.
About the Author Reprints
